Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Taiwan · Delayed Price · Currency is TWD

176.00

+1.00 (0.57%)

Oct 21, 2026, 1:30 PM CST

Market Cap	47.47B -39.7%
Revenue (ttm)	28.49B +49.0%
Net Income	3.77B -22.5%
EPS	14.22 -22.1%
Shares Out	269.69M
PE Ratio	12.30
Forward PE	8.69
Dividend	2.53 (1.44%)
Ex-Dividend Date	Aug 31, 2026

Volume	583,396
Open	177.00
Previous Close	175.00
Day's Range	176.00 - 178.50
52-Week Range	168.31 - 364.76
Beta	0.66
Analysts	Buy
Price Target	292.32 (+66.09%)
Est. Earnings	Nov 12, 2026

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1966

Employees 1,099

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 1795

Full Company Profile

Financial Performance

In 2025, Lotus Pharmaceutical's revenue was 20.51 billion, an increase of 10.36% compared to the previous year's 18.58 billion. Earnings were 4.72 billion, a decrease of -6.82%.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 1795 stock is "Buy." The 12-month stock price target is $292.32, which is an increase of 66.09% from the latest price.

Price Target

$292.32

(66.09% upside)

Analyst Consensus: Buy

Stock Forecasts